When it was discovered that the human body contains endocannabinoid receptors, and that cannabinoids found in marijuana - like THC, CBD, and THCA - organically attach to these receptors, much like aspirin, it opened up a whole new world for medical cannabis.
Now, in collaboration with the CESC (Clinical Endocannabinoid System Consortium), a nonprofit research group, MediCann is in a unique position to better understand the efficacy of cannabis. We know it has proven health benefits, but what types of strains best treat which conditions? What is the most effective dosage? Mode of administration? When is it best to take it? These are all common questions a physician asks when prescribing medicine for a patient's condition.
The Dosing Project is CESC’s flagship clinical study that establishes, in milligrams per kilograms, important dosage information from patient data. It establishes what cannabis plants and products are best for sleep, pain, inflammation, and any other medical condition for which cannabis is used. We’re finding out how different strains treat different conditions in patients. In addition, the CESC is developing strain nomenclature and analyzing plot sampling methods that will move cannabis cultivation for medicine rapidly into the future. This clinical study will improve the efficacy of cannabis for all patients, present and future.
Participation as a patient in The Dosing Project study is FREE and is protected under HIPAA privacy laws. Click Here to Join The Dosing Project Study
If you or your organization would like to sponsor or become a member of the Dosing Project, click here.
Jean Talleyrand, M.D.,
Co-contributor: Christopher Lindquist
MediCann Media Director